ATE355520T1 - Kristallstruktur von bace und verwendungen dafür - Google Patents

Kristallstruktur von bace und verwendungen dafür

Info

Publication number
ATE355520T1
ATE355520T1 AT01973243T AT01973243T ATE355520T1 AT E355520 T1 ATE355520 T1 AT E355520T1 AT 01973243 T AT01973243 T AT 01973243T AT 01973243 T AT01973243 T AT 01973243T AT E355520 T1 ATE355520 T1 AT E355520T1
Authority
AT
Austria
Prior art keywords
bace
crystal structure
agents
alzheimer
beta
Prior art date
Application number
AT01973243T
Other languages
English (en)
Inventor
Rajiv Choppa
Kristine Svenson
Bethany Annis
Tatos N Akopian
Jonathan Bard
Mark Lloyd Stahl
William S Somers
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE355520T1 publication Critical patent/ATE355520T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
AT01973243T 2000-09-22 2001-09-19 Kristallstruktur von bace und verwendungen dafür ATE355520T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23457600P 2000-09-22 2000-09-22

Publications (1)

Publication Number Publication Date
ATE355520T1 true ATE355520T1 (de) 2006-03-15

Family

ID=22881945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01973243T ATE355520T1 (de) 2000-09-22 2001-09-19 Kristallstruktur von bace und verwendungen dafür

Country Status (8)

Country Link
US (1) US7630838B2 (de)
EP (1) EP1327143B1 (de)
AT (1) ATE355520T1 (de)
AU (1) AU2001292843A1 (de)
DE (1) DE60126970T2 (de)
DK (1) DK1327143T3 (de)
ES (1) ES2282292T3 (de)
WO (1) WO2002025276A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
US7806980B2 (en) 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7601528B1 (en) * 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US7384773B1 (en) * 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7524668B1 (en) 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
EP1448218A4 (de) 2001-10-23 2009-01-14 Oklahoma Med Res Found Beta-secretase-hemmer und anwendungsverfahren
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US20040014194A1 (en) * 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US7166454B1 (en) 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
US20040096950A1 (en) * 2002-07-26 2004-05-20 Vuillard Laurent Michel Marie Crystal structure of beta site APP cleaving enzyme (BACE) and methods of use thereof
AU2003285892A1 (en) * 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
EP1554394B1 (de) 2002-10-16 2009-12-16 Isis Innovation Limited Screening-Methoden unter Verwendung eines Strukturmodells von FIH
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
US20070092517A1 (en) * 2005-08-10 2007-04-26 Oklahoma Medical Research Foundation Truncated memapsin 2 compositions and treatments
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2261254A3 (de) 2007-12-21 2011-04-13 Amgen, Inc Antiamyloide Antikörper und deren Verwendungen
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (de) 2009-08-07 2011-02-09 Noscira, S.A. Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
EA201390669A1 (ru) * 2010-11-10 2013-11-29 Дженентек, Инк. Способы и композиции для иммунотерапии заболеваний нервной системы
US9284296B2 (en) 2010-11-22 2016-03-15 Aubergine Pharmaceuticals Llc Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
WO2015109275A1 (en) * 2014-01-20 2015-07-23 New York University Atomic model for janus kinase-2 (jak2) and uses thereof
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
US11008403B2 (en) 2014-11-19 2021-05-18 Genentech, Inc. Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
JPH11507538A (ja) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
EP0848062A3 (de) 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartylprotease ASP1
GB9626022D0 (en) 1996-12-14 1997-01-29 Smithkline Beecham Plc Novel compounds
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME

Also Published As

Publication number Publication date
AU2001292843A1 (en) 2002-04-02
EP1327143B1 (de) 2007-02-28
EP1327143A1 (de) 2003-07-16
DE60126970D1 (de) 2007-04-12
US20020055459A1 (en) 2002-05-09
DK1327143T3 (da) 2007-07-02
ES2282292T3 (es) 2007-10-16
DE60126970T2 (de) 2007-11-22
EP1327143A4 (de) 2005-02-09
US7630838B2 (en) 2009-12-08
WO2002025276A1 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DE60126970D1 (de) Kristallstruktur von bace und verwendungen dafür
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
CY1112271T1 (el) Διαδερμικα συστηματα οπιοειδων περισταλτικα της απροσφορης χρησης
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
BR0107691A (pt) Sapogeninas substituìdas e seu uso
ATE510957T1 (de) Enzyme geeignet zum ändern der eigenschaften von polyester
TR200101400T2 (tr) 2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
TR199802704T2 (xx) H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
FI960850A0 (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
DE50108409D1 (de) Behandlung von oberflächen zur temporären verbesserung des schmutzablöseverhaltens
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
TR200002939T2 (tr) Paroksetin maleat
WO2002004521A3 (en) Proteins with integrin-like activity
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
ATE389029T1 (de) Protease assay zur kontrolle medikamentöser therapie
DE60113535D1 (de) Kompositionen und verwendungen von cgi-69
NZ514691A (en) Method to type prion proteins
DE60034249D1 (de) Kombination enthaltend cyamemazine und ein atypisches neuroleptikum

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties